Cancer Immunotherapy Pilot Program
保存版の掲載情報です。最新の営業状況・料金・利用条件は出典をご確認ください。
保存されている情報
The United States Patent and Trademark Office (USPTO or Office) is implementing a pilot program to provide for earlier review of patent applications pertaining to cancer immunotherapy ("Cancer Immunotherapy Pilot Program" or "Pilot Program") in support of the White House national $1 billion initiative to achieve ten years' worth of cancer research in the next five years ("National Cancer Moonshot"). The USPTO will advance applications containing a claim(s) to a method of treating a cancer using immunotherapy out of turn for examination if the applicant files a grantable petition to make special under the Pilot Program. The objective of the Pilot Program is to complete the examination of the application within twelve months of special status being granted. Under the Cancer Immunotherapy Pilot Program, an application will be advanced out of turn for examination without meeting all of the current requirements of the accelerated examination program (e.g., the requirement for an examination support document) or the Prioritized Examination (Track I) program. This notice outlines the conditions, eligibility requirements, and guidelines of the Pilot Program.
- Current entry point
- www.federalregister.gov/documents/2016/06/29/2016-15533/cancer-immunotherapy-pilot-program (permanent link in the Federal Register, verified 2026-09-30)
- Legacy system and where it moved
- No legacy system name mention in title or summary )
- Fee
- Fee mentioned in title or summary (Confirmed in the document text)
- What you need (account or API key)
- No account or key mention in title or summary )
- Published
- 2016-06-29
- Document type
- Notice
原データ更新日：2026-10-06
保存版に記録された日付です。今回の実装・デプロイ日ではありません。